New Delhi, April 4 – India’s drug regulators are increasing their oversight of rapidly growing weight-loss and diabetes therapies, particularly GLP-1 receptor agonists, amid rising demand and the anticipated entry of cheaper generic versions into the domestic market.This move comes as the...
New Delhi, March 24 To ensure ethical pharmaceutical practices in the supply chain of weight-loss drugs of the GLP-1 class, the Drugs Controller General of India (DCGI) has intensified its regulatory surveillance against the unauthorized sale and promotion of the medications.To this end...